Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
10 2021
Historique:
received: 28 04 2021
revised: 21 09 2021
accepted: 22 09 2021
pubmed: 11 10 2021
medline: 9 2 2022
entrez: 10 10 2021
Statut: ppublish

Résumé

Severe cholinergic degeneration is known to occur in Parkinson's disease (PD) and is thought to play a primary role in the cognitive decline associated with this disease. Although cholinergic losses occur in all patients with PD, cognitive performance remains normal for many of them, suggesting compensatory mechanisms in those. This exploratory study aimed at verifying if normal cognition in PD may involve distinctive features of the brain cholinergic systems. Following extensive neuropsychological screening in 25 patients with PD, 12 were selected and evenly distributed between a cognitively normal (PD-CN) group, and a mild cognitive impairment (PD-MCI) group. Each group was compared with matched healthy volunteers (HV) on standardized cognitive scales (MoCA, PDCRS), and PET imaging with [ [ These findings suggest a compensatory upregulation of the hippocampal cholinergic innervation in PD-CN, which might underly normal cognitive performances in spite of cortical cholinergic denervation in other regions.

Sections du résumé

BACKGROUND
Severe cholinergic degeneration is known to occur in Parkinson's disease (PD) and is thought to play a primary role in the cognitive decline associated with this disease. Although cholinergic losses occur in all patients with PD, cognitive performance remains normal for many of them, suggesting compensatory mechanisms in those.
OBJECTIVES
This exploratory study aimed at verifying if normal cognition in PD may involve distinctive features of the brain cholinergic systems.
METHODS
Following extensive neuropsychological screening in 25 patients with PD, 12 were selected and evenly distributed between a cognitively normal (PD-CN) group, and a mild cognitive impairment (PD-MCI) group. Each group was compared with matched healthy volunteers (HV) on standardized cognitive scales (MoCA, PDCRS), and PET imaging with [
RESULTS
[
CONCLUSION
These findings suggest a compensatory upregulation of the hippocampal cholinergic innervation in PD-CN, which might underly normal cognitive performances in spite of cortical cholinergic denervation in other regions.

Identifiants

pubmed: 34628195
pii: S1353-8020(21)00347-3
doi: 10.1016/j.parkreldis.2021.09.018
pii:
doi:

Substances chimiques

Cholinergic Agents 0
Piperidines 0
Radioactive Tracers 0
fluoroethoxy-benzovesamicol 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

162-166

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Camille Legault-Denis (C)

NeuroQAM Research Centre, Université du Québec à Montréal (UQAM), Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada.

Meghmik Aghourian (M)

NeuroQAM Research Centre, Université du Québec à Montréal (UQAM), Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada.

Jean-Paul Soucy (JP)

McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada; PERFORM Research Centre, Concordia University, Canada.

Pedro Rosa-Neto (P)

McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada; McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Canada.

Alain Dagher (A)

McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada.

Etienne Aumont (E)

NeuroQAM Research Centre, Université du Québec à Montréal (UQAM), Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada.

Rebekah Wickens (R)

NeuroQAM Research Centre, Université du Québec à Montréal (UQAM), Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada.

Marc-André Bedard (MA)

NeuroQAM Research Centre, Université du Québec à Montréal (UQAM), Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, Canada; McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Canada. Electronic address: bedard.marc-andre@uqam.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH